Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Plasma cell 3Other solid neoplasm 2Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Myeloid 1Gastrointestinal 1Classical hematology 1

Conditions

Multiple Myeloma 3Recurrence 1Myeloproliferative Disorders 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dexamethasone 882Bortezomib 481Lenalidomide 467Cyclophosphamide 367Melphalan 276Calcium Dobesilate 265daratumumab 241pomalidomide 216carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 70Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 60Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
darinaparsin × Plasma cell × Clear all
NCT00423644 2013-11-14

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Alaunos Therapeutics

Phase 2 Unknown
17 enrolled
Plasma cell

Multiple Myeloma

NCT00303199 2012-07-19

Study of ZIO-101 in Multiple Myeloma

Alaunos Therapeutics

Phase 1/2 Completed
35 enrolled
Plasma cell

Multiple Myeloma

NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡